Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3576-3584

  Tschan, Serena ^a   Brouwer, Arwin J ^b   Werkhoven, Paul R ^b   Jonker, Anika M ^b   Wagner, Lena ^c   Knittel, Sarah ^c   Aminake, Makoah Nigel ^d,e   Pradel, Gabriele ^d,e   Joanny, Fanny ^a,c   Liskamp, Rob M J ^b,f   Mordmüller, Benjamin ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Centre de Recherches Médicales de Lambaréné HÔpital Albert Schweitzer   (Gabon)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; CHLOROQUINE; EPOXOMICIN; FLUORIDE; PEPTIDO SULFONYL FLUORIDE DERIVATIVE; PRIMAQUINE; PROTEASOME INHIBITOR; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOTOXICITY; GAMETOCYTE; HELA CELL; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MALARIA; MICROBIAL GROWTH; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE; FEMALE; HEK293 CELLS; HELA CELLS; HUMANS; LEUPEPTINS; MICE; OLIGOPEPTIDES; PARASITIC SENSITIVITY TESTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; SCHIZONTS; SULFINIC ACIDS;

EID: 84880323005     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00742-12     Document Type: Article

References (38)

1. Crompton PD, Pierce SK, Miller LH. 2010. Advances and challenges in malaria vaccine development. J. Clin. Invest. 120:4168-4178.
2. Mordmüller B, Kremsner PG. 2006. Malarial parasites vs. antimalarials: never-ending rumble in the jungle. Curr. Mol. Med. 6:247-251.
3. Aregawi M, Cibulskis RE, Lynch M, Williams R, World Health Organization Global Malaria Programme. 2011. World malaria report 2011. World Health Organization, Geneva, Switzerland.
4. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
5. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
6. Noedl H, Socheat D, Satimai W. 2009. Artemisinin-resistant malaria in Asia. N. Engl. J. Med. 361:540-541.
7. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodríguez MH, Sinden R, Slutsker L, Tanner M. 2011. A research agenda to underpin malaria eradication. PLoS Med. 8:e1000406. doi:10.1371/journal.pmed. 1000406.
8. Gates B, Gates M. 2007. Malaria forum keynote address. Bill & Melinda Gates Foundation, Seattle, W. A.
9. Kappe SHI, Vaughan AM, Boddey JA, Cowman AF. 2010. That was then but this is now: malaria research in the time of an eradication agenda. Science 328:862-866.
10. Roll Back Malaria Partnership. 2008. Global malaria action plan (GMAP). Roll Back Malaria Partnership, Geneva, Switzerland.
11. Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu. Rev. Biochem. 67:425-479.
12. Nandi D, Tahiliani P, Kumar A, Chandu D. 2006. The ubiquitinproteasome system. J. Biosci. 31:137-155.
13. Löwe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. 1995. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 268:533-539.
14. Seemüller E, Lupas A, Stock D, Löwe J, Huber R, Baumeister W. 1995. Proteasome from Thermoplasma acidophilum: a threonine protease. Science 268:579-582.
15. Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, Bartunik HD, Huber R. 1997. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386:463-471.
16. Groll M, Bochtler M, Brandstetter H, Clausen T, Huber R. 2005. Molecular machines for protein degradation. Chembiochem 6:222-256.
17. Petroski MD. 2008. The ubiquitin system, disease, and drug discovery. BMC Biochem. 9(Suppl 1):S7. doi:10.1186/1471-2091-9-S1-S7.
18. Tsukamoto S, Yokosawa H. 2009. Targeting the proteasome pathway. Expert Opin. Ther. Targets 13:605-621.
19. Aminake MN, Arndt H-D, Pradel G. 2012. The proteasome of malaria parasites: a multi-stage drug target for chemotherapeutic intervention? Int. J. Parasitol. Drugs Drug Resist. 2:1-10.
20. Chung D-WD, Le Roch KG. 2010. Targeting the Plasmodium ubiquitin/ proteasome system with anti-malarial compounds: promises for the future. Infect. Disord. Drug Targets 10:158-164.
21. Tschan S, Mordmüller B, Kun JFJ. 2011. Threonine peptidases as drug targets against malaria. Expert Opin. Ther. Targets 15:365-378.
22. Aminake MN, Schoof S, Sologub L, Leubner M, Kirschner M, Arndt H-D, Pradel G. 2011. Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast. Antimicrob. Agents Chemother. 55:1338-1348.
23. Lindenthal C, Weich N, Chia YS, Heussler V, Klinkert MQ. 2005. The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites. Parasitology 131:37-44.
24. Prudhomme J, McDaniel E, Ponts N, Bertani S, Fenical W, Jensen P, Le Roch K. 2008. Marine actinomycetes: a new source of compounds against the human malaria parasite. PLoS One 3:e2335. doi:10.1371/journal.pone .0002335.
25. Reynolds JM, El Bissati K, Brandenburg J, Günzl A, Mamoun CB. 2007. Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B. BMC Clin. Pharmacol. 7:13. doi:10.1186/1472-6904-7-13.
26. Czesny B, Goshu S, Cook JL, Williamson KC. 2009. The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity. Antimicrob. Agents Chemother. 53:4080-4085.
27. Gantt SM, Myung JM, Briones MR, Li WD, Corey EJ, Omura S, Nussenzweig V, Sinnis P. 1998. Proteasome inhibitors block development of Plasmodium spp. Antimicrob. Agents Chemother. 42:2731-2738.
28. Brouwer AJ, Ceylan T, van der Linden T, Liskamp RMJ. 2009. Synthesis of-aminoethanesulfonyl fluorides or 2-substituted taurine sulfonyl fluorides as potential protease inhibitors. Tetrahedron Lett. 50:3391-3393.
29. Brouwer AJ, Ceylan T, Jonker AM, van der Linden T, Liskamp RMJ. 2011. Synthesis and biological evaluation of novel irreversible serine protease inhibitors using amino acid based sulfonyl fluorides as an electrophilic trap. Bioorg. Med. Chem. 19:2397-2406.
30. Brouwer AJ, Jonker A, Werkhoven P, Kuo E, Li N, Gallastegui N, Kemmink J, Florea BI, Groll M, Overkleeft HS, Liskamp RMJ. 2012. Peptido sulfonyl fluorides as new powerful proteasome inhibitors. J. Med. Chem. 55:10995-11003.
31. Binh VQ, Luty AJ, Kremsner PG. 1997. Differential effects of human serum and cells on the growth of Plasmodium falciparum adapted to serum-free in vitro culture conditions. Am. J. Trop. Med. Hyg. 57:594-600.
32. Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M. 2005. Simple histidine-rich protein 2 double-site sandwich enzymelinked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob. Agents Chemother. 49:3575-3577.
33. Mordmüller B, Fendel R, Kreidenweiss A, Gille C, Hurwitz R, Metzger WG, Kun JFJ, Lamkemeyer T, Nordheim A, Kremsner PG. 2006. Plasmodia express two threonine-peptidase complexes during asexual development. Mol. Biochem. Parasitol. 148:79-85.
34. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
35. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. 2004. Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug Discov. 3:509-520.
36. Kessler BM, Tortorella D, Altun M, Kisselev AF, Fiebiger E, Hekking BG, Ploegh HL, Overkleeft HS. 2001. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem. Biol. 8:913-929.
37. Kreidenweiss A, Kremsner PG, Mordmüller B. 2008. Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon. Malar. J. 7:187. doi:10.1186/1475-2875-7-187.
38. Vosyka O, Vinothkumar KR, Wolf EV, Brouwer AJ, Liskamp RMJ, Verhelst SHL. 2013. Activity-based probes for rhomboid proteases discovered in a mass spectrometry-based assay. Proc. Natl. Acad. Sci. USA 110:2472-2477.